Skip to main content

Table 2 Procedures and therapies

From: Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients

  All patients Nonsurvivors Survivors P valuea
N 31 23 8  
Noninvasive ventilation, n (%);
days, median (IQR)
14 (45.2);
2 (1–3)
8 (34.8);
2 (1–3)
6 (75.0);
2 (1–4)
0.097
Invasive ventilation, n (%);
days, median (IQR)
27 (87.1);
8 (4–17)
22 (95.7);
8 (2–17)
5 (62.5);
11 (5–17)
0.043
High-frequency oscillation 11 (35.5) 11 (47.8) 0 (0.0) 0.028
Prone positioning, n (%);
days, median (IQR)
5 (16.1);
4 (2–5)
5 (21.7);
4 (2–5)
0 (0.0);
0 (0.0)
1.00
ECMO, n (%);
days, median (IQR)
1 (3.2);
13 (13–13)
1 (4.3);
13 (13–13)
0 (0.0);
0 (0.0)
1.00
Vasopressorsb, n (%);
days, median (IQR)
25 (80.6);
4 (2–9)
22 (95.7);
5 (2–9)
3 (37.5);
3 (2–3)
0.002
Intermittent hemodialysis, n (%);
days, median (IQR)
3 (9.7);
5 (2–5)
2 (8.7);
4 (2–4)
1 (12.5);
7 (7–7)
1.00
Continuous RRT, n (%);
days, median (IQR)
16 (51.6);
6 (2–11)
14 (60.9);
7 (3–11)
2 (25.0);
2 (1–2)
0.113
Medications, n (%)
 Oseltamivir 20 (64.5) 15 (65.2) 5 (62.5) 0.484
 Ribavirin/interferon alfa-2a 13 (41.9) 9 (39.1) 4 (50.0) 0.507
 Neuromuscular blockers 12 (38.7) 10 (43.5) 2 (25.0) 0.465
 Steroidsc 8 (25.8) 6 (26.1) 2 (25.0) 0.954
  1. ECMO extracorporeal membrane oxygenator, IQR interquartile range, RRT renal replacement therapy
  2. aComparisons done for frequencies
  3. bNorepinephrine
  4. cIntravenous hydrocortisone (200–300 mg per day) in four patients and methyprednisolone in four patients (maintenance therapy for underlying disease)